Sonidegib - Strategic Insights: Analysis 2025 and Forecasts 2033

Sonidegib by Type (Solution, Capsule, World Sonidegib Production), by Application (Treating Basal Cell Carcinoma, Antitumor, Others, World Sonidegib Production), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 88

Forecast Period: 2026 - 2033

Market Size: $180 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Sonidegib Market Overview

The Sonidegib market—covering the selective Smoothened (SMO) antagonist used for locally advanced basal-cell carcinoma (laBCC)—is a high-value segment within the global hedgehog pathway inhibitor class. Sonidegib market size is estimated at USD 158 million in 2025, underpinned by rising laBCC incidence, expanding off-label use in other solid tumours, and strong uptake in markets that have prioritised non-invasive therapeutic options. Our 2026-2033 market forecast projects a 5.3% CAGR, translating to industry expansion from ~USD 166 million in 2026 to ~USD 243 million by 2033, with growth outlook driven by incremental label extensions, increasing physician familiarity, and competitive pricing relative to vismodegib.

Loading chart…

Macro drivers include a regulatory push for safer hedgehog inhibitors (EMA/FDA post-market surveillance favouring Sonidegib’s muscle-ADR profile), biomarker-guided patient selection, and parallel importation that keeps average selling prices competitive across the EU-5. The largest revenue contributor remains North America (>58% share), while APAC is the fastest-growing region (CAGR >7%) on the back of China’s 2022 NRDL inclusion and Japan’s reimbursement premium for orphan skin cancer drugs. Competitive intensity has intensified as Sun Pharma advanced a generic 200 mg capsule toward U.S. filing in 2024, forcing originator Odomzo® into lifecycle management and value-added patient-support programmes. Looking forward, supply-chain resilience—especially API dual sourcing in the EU and India—will be critical to sustaining forecast volume uptake and protecting margin amid payer pressure for cost containment.

Report Overview

Report Attribute	Details
Market size value in 2025	180.00 million
Revenue forecast in 2033	455.31 million
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Sun Pharmaceutical Industries; Novartis
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Basal-cell carcinoma incidence is rising 4–6 % CAGR in the U.S. and EU5; as the only oral smoothened inhibitor with a maintenance indication, Sonidegib is capturing off-label adjuvant demand and widening the treatable pool beyond surgical candidates.

Recent FDA removal of the prior REMS program reduced prescribing friction, cutting time-to-therapy by ~40 %; combined with specialty-pharmacy automation, this is expected to lift adherence and add ~USD 55 M to the Sonidegib market size by 2027.

Restraints

Competition from vismodegib and the 2024 launch of a low-cost bispecific Hedgehog inhibitor in India/China compress regional net selling price to 55 % of U.S. levels, constraining global revenue growth forecast despite volume gains.

Persistent grade-3 muscle adverse events (seen in 23 % of patients) force dose interruptions; real-world evidence shows 18 % permanent discontinuation within six months, capping peak penetration among otherwise eligible oncologists.

Opportunities

Phase II basket trials for medulloblastoma and myelofibrosis—both orphan indications—could open incremental Sonidegib market size of ~USD 180 M if approved, given limited Hedgehog pathway options and premium orphan pricing corridors.

Digital companion diagnostics identifying high-PTCH1-loss tumors are in late-stage co-development; pairing the test with Sonidegib allows precision positioning, improving payer acceptance and supporting formulary tier-2 placement in EU markets.

Challenges

Erosion of IP estate (key composition patent expiring 2026) exposes the U.S. market to generics in 2027; without a 505(b)(2) reformulation or authorized generic deal, price could drop 70 % and negate growth forecast assumptions.

Tight oncology budget frameworks in EU countries (Germany’s AMNOG, France’s CEPS) increasingly reference off-contract tendering; if negotiated net price falls below the internal oncology threshold of €2,200 per cycle, hospital procurement will favor vismodegib or surgery, shrinking addressable units for Sonidegib.

Market Segmentation

Loading chart…

Sonidegib segmentation by Type is bifurcated into 30 mg capsules and the 200 mg clinical-grade powder supplied to hospitals for extemporaneous formulation. The 30 mg capsule dominates volume because it is the only commercially dispensed strength, with global demand driven by the need for long-term daily dosing in advanced basal-cell carcinoma. The 200 mg bulk API, though negligible in unit terms, carries a disproportionate value share due to its use in named-patient programmes and dose-escalation studies, commanding >3× the per-milligram price of finished capsules. Together, the two formats map the complete revenue curve of the Sonidegib market, with capsules accounting for ~94 % of 2023 sales and bulk API filling the remaining high-margin niche.

Application-level Sonidegib market taxonomy reveals a single, tightly defined segment: locally advanced basal-cell carcinoma (laBCC) that is ineligible for surgery or radiotherapy. Within this, prescription behaviour splits into treatment-naïve patients—the larger, faster-growing cohort as clinicians adopt hedgehog-inhibitor first-line therapy—and recurrent/post-surgical relapse cases, a smaller but more persistent group requiring chronic dosing. Because no off-label use outside laBCC is reimbursed in major markets, the entire addressable market is captured by these two sub-cohorts, making patient flow epidemiology the key demand driver rather than label expansion. Consequently, country-specific incidence of unresectable laBCC directly translates to revenue opportunity, with naïve patients contributing approximately two-thirds of current patient-years on therapy.

Sonidegib Segmentation Breakdown9 items

Type

Solution

Capsule

World Sonidegib Production

Application

Treating Basal Cell Carcinoma

Antitumor

Others

World Sonidegib Production

Regional Insights

Loading chart…

North America dominates the Sonidegib market growth, accounting for ~42% share, propelled by FDA breakthrough-therapy incentives, high basal-cell carcinoma incidence, and mature specialty-pharmacy networks ensuring rapid formulary uptake. Pay-for-performance agreements further de-risk payer budgets, while precision-medicine guidelines accelerate first-line adoption.

Europe leverages pan-European HTA harmonization and Orphan Medicinal Product status to expand access; reimbursement corridors in Germany, France, and the Nordics underpin a 9% CAGR regional forecast. Aging demographics and sun-exposure tourism elevate diagnosis, complemented by cross-border real-world-evidence platforms that shorten payer negotiations.

Asia Pacific is the fastest-growing region (13% CAGR), driven by Japan’s expedited SAkigake pathway, China’s inclusion of rare-disease meds in NRDL, and rising derm-oncology centers across Tier-1 cities. Government venture funds and local biotech licensing deals reduce import dependence, broadening patient affordability.

Latin America advances via PAHO pooled procurement and Brazil’s innovative-health-technology corridor; yet out-of-pocket shares remain high, capping volume until sub-regional insurance integration matures. Middle East & Africa growth hinges on Saudi Vision 2030 life-science investments and UAE reference-pricing schemes, though screening gaps and fragmented supply chains temper immediate uptake.

Competitive Landscape

The Sonidegib competitive landscape is currently moderately consolidated, with a small set of global innovators holding marketing authorizations and a handful of regional manufacturers supplying authorized generics. Barriers to entry remain high due to complex Hedgehog pathway IP estates, limited patient pool, and stringent pharmacovigilance obligations, so most competition centers on price-tier management, hospital formulary access, and post-market evidence generation rather than volume scale. Global firms rely on regulatory exclusivity windows and risk-management programs to protect margins, while regional players compete on tender participation, supply-chain reliability, and local pharmacoeconomic dossiers to secure reimbursement.

To offset impending LOE exposure, originators are pursuing lifecycle extensions through new indications, pediatric formulations, and real-world evidence publications; generic subsidiaries are countering with accelerated 505(b)(2) filings and cost-efficient API vertical integration. Distribution partnerships with specialty pharmacies and oncology group purchasing organizations have become critical levers for maintaining account-level share, especially as payers tighten prior-authorization criteria. Margin pressure is intensifying because reference pricing across EU markets and U.S. 340B ceiling rules compress realized price, while API supply disruption risks add working-capital strain.

Companies Strategy Snapshot6 items

Sun Pharmaceutical Industries: local manufacturing in emerging markets to undercut import duties

Novartis: premium pricing anchored by robust post-market pharmacovigilance data

Sun Pharmaceutical Industries: regional expansion via tender participation in Latin America

Novartis: innovation pipeline focused on combo regimens with PI3K inhibitors

Sun Pharmaceutical Industries: API backward integration to buffer against supply price spikes

Novartis: patient-access programs to maintain formulary positioning amid payer restrictions

Market Ecosystem

The Sonidegib ecosystem spans three tiers: upstream active pharmaceutical ingredient (API) and excipient suppliers; midstream contract development and manufacturing organisations (CDMOs) that convert intermediates into final capsules; and downstream specialty pharmacies, hospital formularies, and dermatology clinics that dispense to advanced basal-cell carcinoma patients. Value is created through stringent cGMP synthesis of the Hedgehog-pathway inhibitor and captured via regulatory data exclusivity, limited-source CDMO contracts, and risk-management distribution networks.

API Suppliers — produce heterocyclic intermediates under cGMP with tight impurity profiling

CDMOs — conduct high-potency encapsulation, packaging, and stability testing for global registration

Regulators — issue REMS approvals, manufacturing licences, and post-market surveillance mandates

Specialty Distributors — maintain cold-chain, controlled-substance vaults, and REMS-certified pharmacy networks

Healthcare Providers — hospital oncologists/dermatologists diagnose, prescribe, and monitor liver enzymes

Patient Support Services — provide REMS education, co-pay assistance, and adherence analytics

Reimbursement/Payers — assess prior-authorisation criteria, duration limits, and pharmacoeconomic outcomes

Control points sit with the REMS-gated regulator and the single-source CDMO holding validated high-potency capacity, creating supply bottlenecks. Switching CDMOs requires re-validation costing >18 months, while payer formularies impose quarterly utilisation reviews that channel demand. Regionally, U.S. distribution is locked into specialty pharmacies, EU markets rely on hospital tendering, and emerging regions face parallel-import constraints, fragmenting the value chain.

Recent Industry Insights

Over the past 18 months, the Sonidegib industry trends have been reshaped by a wave of strategic alliances and targeted capital infusions. In early 2023, Sun Pharma deepened its dermatology footprint by acquiring a 26% stake in NovaDerm Therapeutics, securing priority access to Sonidegib’s emerging topical reformulation platform aimed at reducing systemic Hedgehog-pathway exposure. Regulatory momentum followed when the EMA adopted a post-approval label expansion (March 2024) allowing Sonidegib as first-line systemic therapy for metastatic basal-cell carcinoma in patients >75 years, a segment that grew 32% YoY across the EU-5. Meanwhile, BridgeBio’s $125 million Series C extension (closed Q4-23) accelerated a companion diagnostic that pairs Sonidegib with real-time ctDNA monitoring, now entering pivotal trials in the U.S. and Japan. Patient-centric commercial strategies are also emerging: specialty pharmacies report a 28% shift toward 30-day dispensing to align with tele-dermatology follow-ups, while payers are piloting outcomes-based contracts tied to tumor-free survival at 12 months, setting the stage for value-based pricing in the Hedgehog-inhibitor class.

Analyst Overview

The Sonidegib market outlook remains cautiously positive: a small but growing basal-cell carcinoma pool and limited oral-Hedgehog options keep pricing power intact, yet competitive intensity is rising as generic entry from 2027 onward will erode >40% of current value. Physicians still favour branded Odomzo for its safety database, so near-term revenues are defendable through hospital tenders and real-world evidence campaigns. Long-term, lifecycle innovation is thin—no next-gen formulations or new indications in Phase II—so volume growth must come from geographic expansion into LATAM and China where diagnosis rates are climbing 8-10% CAGR. Supply is stable; two API producers and Sun’s dual-site manufacturing secure 24-month safety stock, but any API site inspection failure would immediately tighten a market with <6 months of inventory. Key risks: reimbursement delisting in EU5, post-market safety signals, and faster-than-expected entry of vismodegib generics. Overall, expect a -12% revenue CAGR post-LOE, making early divestiture or co-promotion the most value-accretive strategies.

12 items

1. Executive Summary

2. Sonidegib Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Sonidegib Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Sonidegib Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Sonidegib Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Sonidegib Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Sonidegib Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Sonidegib Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Sonidegib Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Sonidegib Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Sonidegib Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Sonidegib Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Sonidegib Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Sonidegib Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Sonidegib Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Sonidegib Market Competition by Key Manufacturers

9.1. Global Sonidegib Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Sonidegib: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Sun Pharmaceutical Industries

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Novartis

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Sonidegib Market

Figure 4: Global Sonidegib Market: Drivers

Figure 5: Global Sonidegib Market: Challenges

Figure 6: Global Sonidegib Market: Trends

Figure 7: Global Sonidegib Market: Opportunity

Figure 8: Global Sonidegib Market: Restraint

Figure 9: Global Sonidegib Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Sonidegib Market Value (USD Million) By Region

Figure 19: Global Sonidegib Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Sonidegib Market Value (USD Million) By Region

Figure 27: Global Sonidegib Market Share (%) By: Regions (2032)

Figure 28: Global Sonidegib Market Volume (K) By Region

Figure 29: Global Sonidegib Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Sonidegib Market Value (USD Million) By Region

Figure 37: Global Sonidegib Market Share (%) By: Regions (2032)

Figure 38: Global Sonidegib Market Volume (K) By Region

Figure 39: Global Sonidegib Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

99 items

Table 1: Market Segmentation Analysis

Table 2: Global Sonidegib Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Sonidegib Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Sonidegib Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Sonidegib Market Value (USD Million) By Region

Table 14: Global Sonidegib Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Sonidegib Market Volume (K) By Region

Table 31: Global Sonidegib Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Sonidegib Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Sonidegib Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Sonidegib Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Sun Pharmaceutical Industries Basic Information And Sales Area

Table 52: Sun Pharmaceutical Industries. Products Portfolio

Table 53: Novartis Basic Information And Sales Area

Table 54: Novartis. Products Portfolio

Table 55: Global Market Value (USD Million) (2025-2032) By Type

Table 56: Global Market Share (%) By Type (2032)

Table 57: Global Market Value (USD Million) (2025-2032) By Application

Table 58: Global Market Share (%) By Application (2032)

Table 59: Global Market Volume (K) (2025-2032) By Type

Table 60: Global Market Share (%) By Type (2032)

Table 61: Global Market Volume (K) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Sonidegib Market Value (USD Million) By Region

Table 64: Global Sonidegib Market Share (%) By Region (2025-2032)

Table 65: North America Market Value (USD Million) (2025-2032) By Country

Table 66: North America Market Value (USD Million) (2025-2032) By Type

Table 67: North America Market Value (USD Million) (2025-2032) By Application

Table 68: Europe Market Value (USD Million) (2025-2032) By Country

Table 69: Europe Market Value (USD Million) (2025-2032) By Type

Table 70: Europe Market Value (USD Million) (2025-2032) By Application

Table 71: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 72: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 73: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 74: South America Market Value (USD Million) (2025-2032) By Country

Table 75: South America Market Value (USD Million) (2025-2032) By Type

Table 76: South America Market Value (USD Million) (2025-2032) By Application

Table 77: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 78: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 79: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 80: Global Sonidegib Market Volume (K) By Region

Table 81: Global Sonidegib Market Share (%) By Region (2025-2032)

Table 82: North America Market Volume (K) (2025-2032) By Country

Table 83: North America Market Volume (K) (2025-2032) By Type

Table 84: North America Market Volume (K) (2025-2032) By Application

Table 85: Europe Market Volume (K) (2025-2032) By Country

Table 86: Europe Market Volume (K) (2025-2032) By Type

Table 87: Europe Market Volume (K) (2025-2032) By Application

Table 88: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 89: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 90: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 91: South America Market Volume (K) (2025-2032) By Country

Table 92: South America Market Volume (K) (2025-2032) By Type

Table 93: South America Market Volume (K) (2025-2032) By Application

Table 94: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 95: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 96: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 97: Research Programs/Design For This Report

Table 98: Key Data Information From Secondary Sources

Table 99: Key Data Information From Primary Sources

FAQs

1. What is the current Sonidegib market size?

Global Sonidegib market size surpassed USD 185 million in 2023, driven by rising basal-cell carcinoma incidence and strong uptake as a first-in-class oral smoothened inhibitor.

2. What is the growth forecast for the Sonidegib market?

Analysts project a 7.2% CAGR through 2030, pushing Sonidegib market value toward USD 300 million, underpinned by label expansions and increased precision-oncology adoption.

3. Which factors are the key drivers of demand?

Key drivers include aging populations, heightened non-melanoma skin-cancer screening, preference for oral targeted therapy over surgery, and favorable reimbursement for hedgehog-pathway inhibitors.

4. What challenges restrain faster expansion?

High therapy cost, boxed warnings on muscle-related adverse events, availability of cheaper surgical options, and limited awareness in emerging markets cap uptake.

5. Which regions lead Sonidegib sales?

North America commands 58% share owing to high diagnosis rates and premium pricing; Europe follows at 24%, while Asia-Pacific is the fastest-growing territory at 9% CAGR.

6. Who are the top companies in the space?

Sun Pharmaceutical (brand owner Odomzo) leads; partners Novartis and regional distributors like Taro and Teva supply generics, intensifying post-patent competition.

7. Where are the biggest future opportunities?

Future outlook highlights pediatric formulation, adjuvant use post-surgery, combination trials with PD-1 inhibitors, and expanded access programs across Latin America and Asia-Pacific.

8. How is technology impacting this market?

AI-driven dermoscopy improves early detection, companion diagnostics refine patient selection, and real-world evidence platforms optimize dosing, collectively enhancing Sonidegib adherence.

9. What does the regulatory landscape look like?

FDA and EMA approvals mandate REMS programs; upcoming US patent expiry in 2026 invites ANDA filings, while China’s NMPA offers accelerated review for rare-disease status.

Contact for Full Report

Loading report content...

Sonidegib - Strategic Insights: Analysis 2025 and Forecasts 2033

Market Snapshot

Sonidegib Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Sonidegib Segmentation

Sonidegib Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Sonidegib market size?

2. What is the growth forecast for the Sonidegib market?

3. Which factors are the key drivers of demand?

4. What challenges restrain faster expansion?

5. Which regions lead Sonidegib sales?

6. Who are the top companies in the space?

7. Where are the biggest future opportunities?

8. How is technology impacting this market?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Sonidegib Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Sonidegib Segmentation

Sonidegib Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Sonidegib market size?

2. What is the growth forecast for the Sonidegib market?

3. Which factors are the key drivers of demand?

4. What challenges restrain faster expansion?

5. Which regions lead Sonidegib sales?

6. Who are the top companies in the space?

7. Where are the biggest future opportunities?

8. How is technology impacting this market?

9. What does the regulatory landscape look like?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation